Research programme: viral infection therapeutics - Toyama Chemical

Drug Profile

Research programme: viral infection therapeutics - Toyama Chemical

Alternative Names: T-1106

Latest Information Update: 14 Dec 2012

Price : $50

At a glance

  • Originator Toyama Chemical
  • Class
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C
  • Discontinued HIV infections; Yellow fever

Most Recent Events

  • 01 Dec 2012 No development reported - Preclinical for Hepatitis C in Japan (PO)
  • 31 Jan 2010 Discontinued - Preclinical for HIV infections in Japan (unspecified route)
  • 31 Jan 2010 Discontinued - Preclinical for Yellow fever in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top